Home › Oral Cancer › Montana › Great Falls
Oral Cancer clinical trials in Great Falls, MT
3 studies for Oral Cancer are looking for participants at sites in and around Great Falls (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
RecruitingPhase 3
- Benefis Sletten Cancer Institute, Great Falls
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RecruitingPhase 2
- Benefis Sletten Cancer Institute, Great Falls
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
RecruitingPhase 2
- Benefis Sletten Cancer Institute, Great Falls
- Great Falls Clinic, Great Falls
About Oral Cancer
Oral cancer can form in the mouth or throat but usually begins in the tongue and floor of the mouth. Read about the common oral cancer symptoms.
More about Oral Cancer on MedlinePlus
Oral Cancer trials in other cities
- Atlanta, GA9 studies
- St. Louis, MO8 studies
- New York City, NY8 studies
- Chicago, IL8 studies
- Durham, NC7 studies
- Houston, TX7 studies
- Milwaukee, WI7 studies
- Kansas City, MO7 studies
- Portland, OR7 studies
- Pittsburgh, PA7 studies
- Ann Arbor, MI7 studies
- Richmond, VA7 studies
Other studies in Great Falls
- Prostate Cancer10 studies
- Non-Small Cell Lung Cancer9 studies
- Lung Cancer9 studies
- Acute Myeloid Leukemia6 studies
- Bladder Cancer5 studies
- Breast Cancer5 studies
- Head and Neck Squamous Cell Carcinoma5 studies
- Colorectal Cancer5 studies
- Melanoma5 studies
- Colon Cancer4 studies
- Endometrial Cancer3 studies
- Rectal Cancer3 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.